Exelixis INC (EXEL) Shareholder Orbimed Advisors LLC Has Lifted Its Holding by $23.33 Million

Exelixis, Inc. (NASDAQ:EXEL) LogoInvestors sentiment decreased to 1.1 in 2019 Q2. Its down 0.79, from 1.89 in 2019Q1. It dived, as 35 investors sold EXEL shares while 87 reduced holdings. 34 funds opened positions while 100 raised stakes. 225.65 million shares or 2.54% less from 231.52 million shares in 2019Q1 were reported. Tiverton Asset Management Ltd Liability, a Delaware-based fund reported 23,348 shares. Moreover, Stevens Mgmt LP has 0.1% invested in Exelixis, Inc. (NASDAQ:EXEL) for 105,097 shares. Cornerstone invested 0.01% in Exelixis, Inc. (NASDAQ:EXEL). Quantbot Techs LP holds 0.01% or 6,100 shares in its portfolio. Riverhead Mgmt Ltd Limited Liability Company holds 32,543 shares. Marshall Wace Ltd Liability Partnership owns 0.09% invested in Exelixis, Inc. (NASDAQ:EXEL) for 499,573 shares. California Pub Employees Retirement System stated it has 0.01% in Exelixis, Inc. (NASDAQ:EXEL). Amundi Pioneer Asset Inc holds 0% or 57,560 shares in its portfolio. Cambridge Advsrs holds 45,786 shares or 0.01% of its portfolio. Kistler stated it has 0% in Exelixis, Inc. (NASDAQ:EXEL). Moreover, D E Shaw & Com Incorporated has 0% invested in Exelixis, Inc. (NASDAQ:EXEL) for 82,820 shares. Plancorp Ltd Com has 0.11% invested in Exelixis, Inc. (NASDAQ:EXEL). Ajo LP accumulated 653,373 shares. Cibc Asset Mngmt has invested 0% in Exelixis, Inc. (NASDAQ:EXEL). Gemmer Asset Ltd Llc stated it has 264 shares.

Orbimed Advisors Llc increased its stake in Exelixis Inc (EXEL) by 39.65% based on its latest 2019Q2 regulatory filing with the SEC. Orbimed Advisors Llc bought 1.11M shares as the company’s stock rose 9.98% . The hedge fund held 3.91M shares of the health care company at the end of 2019Q2, valued at $83.62M, up from 2.80 million at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Exelixis Inc for a number of months, seems to be bullish on the $5.83B market cap company. The stock decreased 0.10% or $0.02 during the last trading session, reaching $19.24. About 2.25 million shares traded. Exelixis, Inc. (NASDAQ:EXEL) has declined 0.93% since September 13, 2018 and is downtrending. It has underperformed by 0.93% the S&P500.

Orbimed Advisors Llc, which manages about $6.70B and $6.46 billion US Long portfolio, decreased its stake in Biomarin Pharmaceutical Inc (NASDAQ:BMRN) by 175,000 shares to 75,000 shares, valued at $6.42M in 2019Q2, according to the filing. It also reduced its holding in Principia Biopharma Inc by 1.00 million shares in the quarter, leaving it with 1.61M shares, and cut its stake in Proqr Thrapeutics N V (NASDAQ:PRQR).

More notable recent Exelixis, Inc. (NASDAQ:EXEL) news were published by: Investorplace.com which released: “8 Biotech Stocks to Watch After the Q2 Earnings Season – Investorplace.com” on August 20, 2019, also Nasdaq.com with their article: “Exelixis (EXEL) to Report Q1 Earnings: What’s in Store? – Nasdaq” published on April 25, 2019, Nasdaq.com published: “Exelixis is Now Oversold (EXEL) – Nasdaq” on April 18, 2019. More interesting news about Exelixis, Inc. (NASDAQ:EXEL) were released by: Finance.Yahoo.com and their article: “Exelixis (NASDAQ:EXEL) Shareholders Have Enjoyed A Whopping 474% Share Price Gain – Yahoo Finance” published on July 18, 2019 as well as Fool.com‘s news article titled: “3 Cancer Treatment Stocks to Buy Right Now – The Motley Fool” with publication date: August 25, 2019.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.